2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of the American …, 2022 - jacc.org
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Applications of artificial intelligence and machine learning in heart failure

T Averbuch, K Sullivan, A Sauer… - … Heart Journal-Digital …, 2022 - academic.oup.com
Abstract Machine learning (ML) is a sub-field of artificial intelligence that uses computer
algorithms to extract patterns from raw data, acquire knowledge without human input, and …

Titration of medical therapy for heart failure with reduced ejection fraction

SJ Greene, GC Fonarow, AD DeVore… - Journal of the American …, 2019 - jacc.org
Background: Guidelines recommend that patients with heart failure with reduced ejection
fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as …

2022 ACC/AHA/HFSA guideline for the management of heart failure

PA Heidenreich, B Bozkurt, D Aguilar, LA Allen… - Journal of Cardiac …, 2022 - Elsevier
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

M Serenelli, M Böhm, SE Inzucchi, L Køber… - European heart …, 2020 - academic.oup.com
Aims Concern about hypotension often leads to withholding of beneficial therapy in patients
with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and …

New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation

M Packer, PA Grayburn - JAMA cardiology, 2020 - jamanetwork.com
Importance Traditionally, physicians distinguished between mitral regurgitation (MR) as a
determinant of outcomes and MR as a biomarker of left-ventricular (LV) dysfunction by …

Blood pressure and safety events with vericiguat in the VICTORIA trial

CSP Lam, H Mulder, Y Lopatin… - Journal of the …, 2021 - Am Heart Assoc
Background Although safety and tolerability of vericiguat were established in the VICTORIA
(Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial …

Medical therapy during hospitalization for heart failure with reduced ejection fraction: the VICTORIA registry

SJ Greene, JA Ezekowitz, KJ Anstrom… - Journal of cardiac …, 2022 - Elsevier
Background For patients hospitalized for heart failure with reduced ejection fraction (HFrEF),
guidelines recommend optimization of medical therapy prior to discharge. The degree to …

[HTML][HTML] Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction

N Girerd, JJ Von Hunolstein, P Pellicori… - ESC heart …, 2022 - ncbi.nlm.nih.gov
Randomized controlled trials (RCTs) have established the efficacy of several therapies to
improve both symptoms and outcomes for patients with heart failure and reduced left …

Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug …

M Packer, M Metra - European Journal of Heart Failure, 2020 - Wiley Online Library
Numerous guideline documents have issued recommendations to clinicians concerning the
treatment of chronic heart failure and a reduced ejection fraction. However, guidelines do …